Eli Lilly and Co. entered a definitive agreement to acquire DICE Therapeutics, Inc., a biopharma company that leverages its DELSCAPE technology platform to develop oral therapeutic candidates to treat chronic diseases in immunology, for approximately $2.4 billion. The transaction has been approved by the boards of directors of both companies.   Dice’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as e...